CION Ameerpet
Fertility & Hormones · Reviewed by CION Oncologists · NABH Accredited
Fertility-Sparing Treatment — Who Actually Qualifies
Keeping the uterus rather than removing it is a recognised option in international guidance, and it is available to a narrow group of women. The criteria are strict, and every one of them exists because the whole approach depends on being genuinely confident the cancer is confined to the lining. This page sets them out plainly so you can work out roughly where you stand before an appointment rather than after. One thing matters more than any single criterion: this has to be established before surgery. Once the uterus has been removed the conversation is over, and it is a conversation that is far easier to have early.
- Grade 1 endometrioid only — higher grades and other types respond poorly and behave differently
- No invasion into the muscle wall — confirmed on MRI, not assumed
- A current wish to conceive — the option exists for fertility, not to avoid an operation
- Ask before anything is scheduled — the window closes the day the uterus is removed
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Criteria, and Why Each One Exists
They are not a checklist assembled arbitrarily. Each answers a specific question about whether the approach is safe.
| Requirement | Why it is there |
|---|---|
| Grade 1 endometrioid carcinoma | The firmest criterion. Grade 1 tumours are the ones that reliably retain hormone receptors and respond to progestin. Grade 2 and 3 tumours respond far less well and behave more aggressively. See endometrial cancer grades. |
| No invasion of the muscle wall | Assessed on MRI. Invasion means the tumour has left the compartment that hormone treatment can reliably reach, and it raises the chance that cells have reached lymph nodes. See MRI staging. |
| No disease outside the uterus | Imaging must show no involvement of the ovaries, the nodes or anywhere beyond. Conservative treatment does nothing for disease that has already travelled. |
| Pathology confirmed by expert review | The distinction between atypical hyperplasia, grade 1 and grade 2 carcinoma decides the entire plan and is a difficult call. It should be reviewed rather than accepted from a single report. |
| A current wish to conceive | The approach carries additional risk in exchange for preserving fertility. It is not offered simply to avoid an operation, and guidance is explicit on this point. |
| Willingness to attend surveillance | Repeat sampling every few months is the mechanism that makes this defensible. A woman who cannot commit to it is not a candidate, and saying so is not a judgement about her. |
| No contraindication to progestin | A history of blood clots, certain liver conditions and some other factors make high-dose progestin unsafe and would need weighing individually. |
Where a criterion is borderline, that is a reason for a specialist opinion rather than an automatic no. A grade reported as “1 to 2”, or imaging described as equivocal for invasion, genuinely warrants review by someone who does this regularly — because the review sometimes changes the answer. What is not reasonable is being refused without the assessment being done.
Did You Know? The single most important thing about eligibility is not any individual criterion — it is timing. Fertility-sparing treatment is an alternative to hysterectomy, so it can only be considered while the uterus is still there. Women are sometimes referred for a fertility opinion after their operation, when nothing can be done. If you are premenopausal, have been diagnosed with endometrial cancer, and might want children, that fact needs to be on the table at the first treatment discussion — not raised once a date has been set. If nobody has asked you about it, say so yourself. Sources: ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESHRE guidance on female fertility preservation.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What the Assessment Actually Involves
Establishing eligibility takes a little time and it is worth doing properly, because the whole approach rests on the answer being right.
- Expert review of the pathology. The slides are examined again, ideally by a pathologist experienced in gynaecological cancer. This is the step most likely to change the answer in either direction.
- MRI of the pelvis. To assess whether there is any invasion into the muscle wall and to look at the ovaries. The single most informative imaging test for this question.
- Hysteroscopy in many centres. So the cavity is seen directly and sampled under vision rather than blind, which gives a more reliable picture of what is there. See hysteroscopy and D&C.
- Molecular testing. Including mismatch repair status — both because it informs the outlook and because a deficient result may indicate Lynch syndrome, which changes the whole conversation about future risk and about the family.
- A fertility assessment. Ovarian reserve and any other fertility factors, because the plan only makes sense if pregnancy is realistically achievable. Referral to reproductive medicine is arranged as a coordinated service.
Diagnosed Young and Nobody Has Asked About Children?
Raise it now rather than later. Assessment takes a pathology review and an MRI, and it must happen before surgery.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
This Question Has to Be Asked Before the Operation
Afterwards there is nothing to decide. If it might matter to you, say so at the first appointment.
Who Is Not Eligible, and Why
Being told no is difficult, and it is easier to accept when the reasoning is clear. These are the situations where the answer is genuinely no rather than negotiable.
Grade 2 or 3 disease
Higher-grade tumours are considerably less likely to retain the hormone receptors through which progestin acts, so response rates are much lower — and they behave more aggressively, meaning the cost of a failed attempt is higher. This is the firmest exclusion in the guidance and it is not a matter of clinician preference. See Grade 3 endometrial cancer.
Non-endometrioid histology
Serous carcinoma, clear cell carcinoma and carcinosarcoma are high grade by definition, are generally hormone-receptor negative, and spread more readily. Hormone treatment has essentially nothing to offer them, and deferring surgery would be actively harmful. See Type 2 endometrial cancer.
Any invasion into the muscle wall
Once the tumour has grown into the myometrium it is outside the compartment that a hormone-releasing device or systemic progestin can reliably reach, and the chance of lymph node involvement rises. Even minimal invasion on MRI closes this route, which is why the imaging has to be good and interpreted by someone experienced.
Disease outside the uterus
Involvement of the ovaries, the lymph nodes or anywhere beyond means the disease is no longer a local problem, and conservative treatment of the lining would leave it untreated. This is why imaging to look beyond the uterus is part of the assessment rather than optional.
Want Your Eligibility Assessed Properly?
Pathology review and MRI to answer it definitively — before any surgery is scheduled. The opinion is free.
If the Answer Is No
For a woman who wanted children, being told she is not eligible is a second loss on top of the diagnosis, and it deserves to be acknowledged rather than passed over.
There are still things worth asking about.
- Ask whether the pathology has been reviewed. If the grade was borderline or the imaging equivocal, a second reading occasionally changes the answer. It does not usually, and it is reasonable to want it done.
- Ask about egg or embryo preservation before treatment. If your ovaries are being removed, or if treatment might affect them, retrieving eggs beforehand may be possible — and it preserves the option of surrogacy later. This is time-critical and needs raising immediately.
- Ask whether the ovaries themselves can be preserved. A separate question from keeping the uterus. In selected premenopausal women with early low-grade disease, retaining the ovaries is sometimes considered. See removing the ovaries and tubes.
- Ask for support. The loss of fertility alongside a cancer diagnosis is a substantial grief, and psycho-oncology exists for exactly this. It is not a comment on how well you are coping. See emotional health after a diagnosis.
And the thing worth holding onto: ineligibility for fertility-sparing treatment usually means the cancer is more than minimal — which means surgery is the treatment that gives you the best chance, and that is the more important consideration.
Why This Assessment Should Not Be Rushed
A pathology review and an MRI take days. The decision they inform is irreversible.
Fertility taken seriously
Slides reviewed, not just the summary line
Tumour board for every diagnosis
Lynch counselling built in
45-minute consultations
Decisions for healing, not billing
Take The Next Step
If You Want Children, Say So at the First Appointment
Not the third. This is the one question that cannot be revisited after surgery.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Fertility-Sparing Eligibility — Frequently Asked Questions
What are the criteria for fertility-sparing treatment?
Seven, and each answers a specific question about whether the approach is safe. The tumour must be a grade 1 endometrioid carcinoma; there must be no invasion into the muscle wall of the uterus on MRI; there must be no evidence of disease outside the uterus including the ovaries; the pathology should be confirmed by expert review rather than accepted from a single report; you must have a current wish to become pregnant; you must be willing to attend repeat endometrial sampling every few months; and there must be no medical reason that high-dose progestin would be unsafe, such as a history of blood clots. These are strict because the whole approach depends on being confident the cancer is confined to the lining.
When do I need to ask about this?
Before any surgery is scheduled, and ideally at the very first treatment discussion. This is the single most important practical point on the page. Fertility-sparing treatment is an alternative to hysterectomy, so it can only be considered while the uterus is still there — once it has been removed, there is nothing to decide. Women are sometimes referred for a fertility opinion after their operation, when it is too late. If you are premenopausal, have been diagnosed with endometrial cancer, and might want children, put that on the table immediately. If nobody has asked you, raise it yourself rather than waiting to be asked.
My grade was reported as "1 to 2". Does that exclude me?
Not automatically, and this is exactly the situation that warrants a specialist opinion rather than a reflex refusal. Distinguishing grade 1 from grade 2 endometrioid carcinoma is one of the less reproducible judgements in gynaecological pathology, and expert review by a pathologist experienced in this area sometimes changes the answer — in either direction. The same applies to imaging described as equivocal for myometrial invasion. What is reasonable is asking for the review to be done before a decision is finalised. What is not reasonable is being refused without the assessment being carried out at all.
Why does it matter whether I currently want to be pregnant?
Because the approach exists to preserve fertility and carries additional risk in exchange for that, and international guidance is explicit that it is for women who wish to conceive rather than for women who would prefer to avoid an operation. Keeping the uterus means accepting a meaningfully higher chance of the cancer returning than hysterectomy would carry, plus a demanding programme of repeat biopsies. That trade-off makes sense in pursuit of a pregnancy. It makes considerably less sense otherwise, which is why the conversation usually also covers an agreement to complete treatment with hysterectomy once childbearing is finished.
What can I do if I am not eligible?
Several things are worth asking about. Request confirmation that the pathology has been reviewed, particularly if the grade was borderline or the imaging equivocal — it does not usually change the answer but it is reasonable to want it checked. Ask urgently about egg or embryo preservation before treatment begins, which may preserve the option of surrogacy later and is time-critical. Ask whether your ovaries can be preserved even though the uterus cannot, which is a separate question and sometimes possible in early low-grade disease. And ask for psychological support: losing fertility alongside a cancer diagnosis is a real grief and there are people whose job this is.
Medical disclaimer: This page sets out eligibility for fertility-sparing treatment of endometrial cancer in general terms and is reviewed by a CION oncologist, following current NCCN and ESGO–ESTRO–ESP guidance. Eligibility depends on pathology and imaging specific to you and can only be established by a specialist team. Assisted reproduction is arranged through reproductive medicine services rather than provided in-house. This is not advice about your own case, and the assessment must be completed before any surgery is scheduled.